FDA Moves to Phase Out Popular Decongestant Ingredient
The U.S. Food and Drug Administration (FDA) is taking steps to remove phenylephrine, a widely used decongestant, from over-the-counter cold and allergy medications. This decision comes after years of debate about the drug’s effectiveness in relieving nasal congestion when taken orally.
Phenylephrine, found in popular products like Sudafed PE and Dayquil, has been a staple in many households for treating cold and allergy symptoms. However, the FDA’s recent proposal to revoke its approval for use in oral medications has sent shockwaves through the pharmaceutical industry and consumer markets alike.
The move follows a unanimous vote by federal advisers declaring oral phenylephrine ineffective for congestion relief. Recent studies have shown that the drug performs no better than a placebo when taken by mouth, contradicting older research that supported its use.
Dr. Leslie Hendeles, a professor at the University of Florida who has long questioned phenylephrine’s efficacy, hailed the decision as a victory for evidence-based medicine. “This is a win for consumers who have been spending their hard-earned money on products that don’t work,” Hendeles stated.
The FDA’s decision affects a significant portion of the over-the-counter medication market, with oral phenylephrine products generating approximately $1.8 billion in annual U.S. sales. However, the agency clarified that phenylephrine remains effective when used in nasal sprays.
As a result of this change, consumers will need to explore alternative congestion relief options. Pseudoephedrine, available behind pharmacy counters with photo ID requirements, remains a viable alternative. Other options include nasal sprays, saline drops, and nasal steroids like Flonase and Nasacort.
The ineffectiveness of oral phenylephrine is attributed to its breakdown in the stomach before reaching the bloodstream. Attempts to increase dosage proved ineffective and potentially risky due to cardiovascular effects.
While the FDA’s decision is a significant step, the process of removing phenylephrine from approved drugs will take time. The agency will accept public comments for six months before finalizing its decision, and companies will have at least a year to comply with the new regulations.
As this regulatory process unfolds, consumers are advised to consult with healthcare professionals about the most effective congestion relief options for their individual needs.
By
